Key Highlights
- Amended filings disclosed a material weakness in internal control over financial reporting, and prior financial statements were not restated.
- A Special Committee terminated the former CEO for Cause on April 30, 2026; he later filed an arbitration demand.
- Cash was $118.3 million at June 30; the company expects it to fund operations into mid to late fiscal 2028.
- The company said on October 15 it may proceed with a planned Fragile X clinical study under its IND.
Anavex Life Sciences (NASDAQ:AVXL) shares were trading near their 52-week low at USD 1.23 on October 19, 2026, down 6.49%. Since midyear, the clinical-stage biotechnology company has filed amended reports on internal controls, regained compliance with a Nasdaq filing rule, held a contested annual meeting and advanced its blarcamesine programs under an interim chief executive.
Controls, late filings and Nasdaq compliance
On August 28, 2026, Anavex filed a 10-K/A for the fiscal year ended September 30, 2025 and a 10-Q/A for the quarter ended December 31, 2025. Both revised its conclusions on controls after the Special Committee terminated the former CEO for Cause on April 30, 2026. Management and the Audit Committee concluded that a material weakness existed at September 30, 2025, and that disclosure controls and internal control over financial reporting were not effective. The company said the reassessment did not result in any misstatement and that it is not restating its financial statements.
Grant Thornton's adverse opinion on internal control, dated August 28, 2026, cites the control environment and information and communication. It states that the former CEO failed to set an appropriate tone at the top and notes a lack of transparency with the board on regulatory, clinical and non-financial matters.
Nasdaq sent a delinquency letter on May 20 because the March 31 quarterly report was late under Listing Rule 5250(c)(1). Anavex filed the March 31 and June 30 reports on August 28, and on September 2 said Nasdaq had confirmed it regained compliance.
Disputes and the contested annual meeting
The former CEO, Christopher Missling, filed an arbitration demand in June alleging wrongful termination, breach of contract and defamation, and sought severance, equity acceleration and damages. On July 6 he filed a New York court summons, individually and derivatively, against four independent directors. The company denies wrongdoing, calls the suit without merit and says it cannot estimate a loss.
At the September 24 annual meeting, which included a proxy contest, all six company nominees were elected and none of the nominees put forward by PVG Asset Management. The company reported on September 28 that a change-in-control provision applied once incumbent directors no longer formed a majority as its incentive plans define it, and all outstanding unvested equity awards vested in full.
Third quarter results, cash and funding
For the fiscal third quarter ended June 30, 2026, Anavex reported net income of $7.8 million, or $0.08 per share, against a net loss of $13.2 million a year earlier. The company attributed the change primarily to reversals of stock-based compensation expense, $7.5 million in general and administrative and $9.9 million in research and development, tied to employee terminations, mainly the former CEO. The nine-month net loss was $3.2 million, or $0.03 per share, compared with $36.6 million, or $0.43.
Cash and cash equivalents were $118.3 million, up from $102.6 million at September 30, 2025, which the company expects to fund operations into mid to late fiscal 2028. It disclosed that it issued 6,026,237 shares for net proceeds of $36.4 million under its 2025 sales agreement and suspended sales once the Special Committee was formed.
Blarcamesine plans for Alzheimer's, Rett and Fragile X
Anavex said it is prioritizing engagement with the FDA on early Alzheimer's disease after submitting all trial data to a newly opened IND, and it plans to discuss a US development path and Phase 3 design. It received EMA scientific advice in June but is not pursuing a European Phase 3 at this time.
For Rett syndrome, the company is moving ahead with an adult Phase 3 study, ANAVEX2-73-RS-005, in about 170 participants with a 16-week double-blind period. On September 9 it said the FDA granted a meeting to discuss adding pediatric patients; no date was given. On October 15 it said the FDA notified it that it may proceed with a planned Fragile X clinical study.






Please wait processing your request...